Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
March 23 2022 - 7:44AM
Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology
company focused on discovering, developing, and commercializing
novel gene therapies, biologicals and vaccines, today announced the
appointment of Marna C. Whittington, PhD, to the Board of
Directors. Her term became effective March 21, 2022.
“We’re extremely pleased to welcome Dr. Marna Whittington to the
Ocugen board,” said Dr. Shankar Musunuri, Chairman of the Board,
Chief Executive Officer, and Co-founder of Ocugen. “Her experiences
will be exceedingly important to our growth strategy as we progress
our modifier gene therapies and vaccine candidate. I also want to
thank Manish Potti for his significant contributions to the Board
and the Company.”
Mr. Potti made the personal decision not to seek another term of
service on the Board of Directors, commenting, “Ocugen is uniquely
positioned for a bright future. Its pipeline and clinical programs
for COVID-19 and ophthalmology are going to be valuable additions
for patients. Shankar and the management team are well-prepared to
handle the road ahead of them, and I wish the company nothing but
continued success.”
Dr. Whittington is a renowned leader within the financial sector
and a sought-after expert serving on numerous boards. She was the
Chief Executive Officer of Allianz Global Investors Capital from
2001 until her retirement in January 2012. Before that, Dr.
Whittington was a corporate officer for Morgan Stanley Investment
Management and the University of Pennsylvania as well as the
Secretary of Finance for the State of Delaware. She currently
serves on the boards of the Salk Institute, Tower Hill School,
Macy’s Inc., the Philadelphia Contributionship (a company founded
by Benjamin Franklin), Phillips 66 and Oaktree Capital
Management.
“This team is making discoveries through courageous innovation
and positioning itself to make significant contributions to the
health of our communities. I appreciate the opportunity to
contribute to its continued success,” said Marna Whittington, PhD,
newly appointed Director of Ocugen’s Board of Directors.
About Ocugen, Inc. Ocugen, Inc. is a
clinical-stage biotechnology company focused on discovering,
developing, and commercializing gene therapies, biologicals and
vaccines that improve health and offer hope for people and global
communities. We are making an impact through courageous innovation,
taking science in new directions in service of patients. Our
breakthrough modifier gene therapy platform has the potential to
treat multiple diseases with one drug and we are advancing research
in other therapeutic areas to offer new options for people with
unmet medical needs. Discover more at www.ocugen.com and follow us
on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (“SEC”), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Ocugen Contact: Ken InchaustiHead,
Investor Relations & CommunicationsIR@Ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024